Oruka Therapeutics (NASDAQ:ORKA) CEO Sells $71,407.70 in Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) CEO Lawrence Otto Klein sold 1,729 shares of the stock in a transaction on Monday, March 16th. The shares were sold at an average price of $41.30, for a total transaction of $71,407.70. Following the completion of the sale, the chief executive officer owned 927,309 shares of the company’s stock, valued at approximately $38,297,861.70. This represents a 0.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Oruka Therapeutics Trading Down 1.1%

Shares of Oruka Therapeutics stock traded down $0.44 during trading on Tuesday, hitting $41.31. 645,354 shares of the stock were exchanged, compared to its average volume of 462,463. The company has a fifty day moving average price of $33.22 and a 200-day moving average price of $27.86. The stock has a market capitalization of $2.05 billion, a price-to-earnings ratio of -22.21 and a beta of -0.38. Oruka Therapeutics, Inc. has a 1-year low of $5.49 and a 1-year high of $42.41.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.16. Equities research analysts forecast that Oruka Therapeutics, Inc. will post -3.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Viking Global Investors LP bought a new position in Oruka Therapeutics during the 3rd quarter worth $51,280,000. Paradigm Biocapital Advisors LP bought a new stake in shares of Oruka Therapeutics in the fourth quarter valued at about $51,840,000. Remedium Capital Partners LLC acquired a new position in shares of Oruka Therapeutics in the fourth quarter valued at about $47,054,000. Avoro Capital Advisors LLC acquired a new position in shares of Oruka Therapeutics in the third quarter valued at about $25,640,000. Finally, Deep Track Capital LP increased its position in Oruka Therapeutics by 38.4% during the third quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock worth $51,051,000 after acquiring an additional 735,983 shares during the period. 56.44% of the stock is owned by institutional investors and hedge funds.

Oruka Therapeutics News Roundup

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Leerink Partners raised its price target on ORKA from $58 to $86 and maintained an “outperform” rating — a large upward revision that signals strong conviction from a prominent analyst. Leerink price target raise
• Positive Sentiment: BTIG Research reiterated a Buy rating on Oruka, reinforcing institutional analyst support that can sustain buying pressure. BTIG Buy Rating Reiterated
• Positive Sentiment: Wedbush reiterated an Outperform rating and Guggenheim reiterated a Buy — multiple confirmations of bullish views from different houses increase the credibility of the upgrade trend. Wedbush Outperform Reiterated
• Positive Sentiment: Several price‑target raises have been reported (including a $50 target in one note), and Wall Street Zen upgraded ORKA — the aggregation of higher targets and upgrades is likely supporting higher valuations. Price Target Raised to $50 Wall Street Zen Upgrade
• Neutral Sentiment: Zacks highlighted that the average analyst price target implies roughly 41.5% upside for ORKA but also cautioned about the metric’s limitations — useful for gauging sentiment but not a guarantee of performance. Zacks analyst consensus piece
• Neutral Sentiment: General market/company news roundups (e.g., MSN) mentioned ORKA among recent movers but added no new company‑specific catalysts; useful for context but not a driver by itself. MSN company news

Analysts Set New Price Targets

ORKA has been the topic of a number of recent analyst reports. BTIG Research reissued a “buy” rating and set a $73.00 target price on shares of Oruka Therapeutics in a report on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Thursday, January 22nd. Wedbush reissued an “outperform” rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a research report on Friday. Barclays raised their target price on shares of Oruka Therapeutics from $48.00 to $50.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, UBS Group began coverage on shares of Oruka Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price target on the stock. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $59.60.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.